FDA approves Irish facility to produce Rhopressa for US market
The FDA has approved Aerie Pharmaceuticals’ sterile fill facility in Athlone, Ireland, for the production of Rhopressa for commercial distribution in the U.S., according to a press release.
“What began as a vision to control our destiny from a manufacturing standpoint in 2015 has led to the FDA approval of our facility earlier this year to produce Rocklatan, and now Rhopressa, for commercial distribution in the United States,” Vicente Anido Jr., PhD, chairman and CEO of Aerie, said in the release.
Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) shipments to the U.S. have begun, and Aerie is aiming to begin shipping Rhopressa (netarsudil ophthalmic solution 0.02%) to the U.S. later this year. The goal is to have the Athlone facility supply ophthalmic products for every market Aerie operates in, the release said.